Phase 2 N=116 Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
Leukemia
Primary: Median Time to Engraftment of Neutrophils — 11; 11 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
Brain Cancer
Primary: SUV Measures
Phase 2 N=80 Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
Bladder Cancer · High Risk Superficial
Primary: Response Rate — 62; 18 Participants
Phase 2 N=102 Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Metastatic Colorectal Carcinoma · Stage IV Colorectal Cancer AJCC v8 · Stage IVA Colorectal Cancer AJCC v8
Primary: Progression Free Survival (PFS) — 2.3; 2.2 months
Phase 2 N=502 A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
Asthma
Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049
Phase 2 N=89 Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A
Influenza A
Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181
Phase 4 N=70 "Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."
Pain
Primary: Neonatal Facial Coding System Score — 4.6; 3.9; 8.3; 8 score on a scale
N/A N=1,771 The Emergency Department Sedation Pilot Trial
Mechanical Ventilation · Respiratory Failure
Primary: Participant Recruitment — 196; 219 Participants
Phase 4 N=17 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale
Phase 3 N=81 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24…
Phase 2 N=51 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Advanced Malignancies · Metastatic Cancer
Primary: Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 4; 5; 4 Participants
Phase 4 N=240 Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section
Nausea · Vomiting · Satisfaction
Primary: Number of Patients With Nausea — 40; 39; 46 Participants — p=0.98
Phase 2 N=12 Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
Sickle Cell Disease · Stroke
Primary: Number of Randomized Participants With Central Nervous System Complications — 1; 4 Participants — p=0.2914
N/A N=14 t-RNS After Hand Recovery in Chronic Stroke
Stroke
Primary: Change From Baseline in Fugl Meyer Upper Extremity Scale at Post Treatment — 35.25; 33.5 score on a scale — p=0.046
N/A N=8 tAN to Mitigate Withdrawal Behaviors in Neonates
Neonatal Abstinence Syndrome
Primary: Number of Subjects With no Adverse Events Related to Bradycardia (HR < 80 Bpm), Worsening of Swallowing or Feeding, Skin Irritation, or Elevation of Neonatal Infant Pain…